Clinical TrialsHigh probability of success for Ph2 REVERT-IPF readout with insightful blinded preliminary analysis, showing positive trends in patient outcomes.
Investment OpportunityThe risk-reward on shares remains favorable with a market capitalization under $250 million, providing an attractive investment opportunity.
Market PositionThere is scarcity value in TTI-101 as the only STAT3 inhibitor in development for IPF in the US, with expected increased strength in the stock as appreciation for its potential grows.